Profil Penggunaan Antikoagulan pada Pasien COVID-19 dengan Komorbid Hipertensi di Rawat Inap RSUD Panembahan, Bantul, Yogyakarta

Rahmat A Hi Wahid, Anis Febri Nilansari, Fitri Andriani Fatimah

Abstract


Hypertension is the highest comorbid group in COVID-19 patients, followed by diabetes mellitus and heart disease. The increase in coagulopathy and thromboembolism secondary to COVID-19 has received global attention, with several surveys and reports of increased mortality. The use of anticoagulants in the treatment of COVID-19 patients needs to be done. This study aims to determine the profile of the use of anticoagulants in COVID-19 patients with hypertension who are hospitalized in Panembahan Hospital, Senopati, Bantul, Yogyakarta. The research method is descriptive observational research using secondary data in the form of medical records. Data were taken retrospectively from the medical records of COVID-19 patients with hypertension who were hospitalized at Panembahan Hospital, Bantul, Yogyakarta for the period 2020-2021. A total of 67 medical records met the inclusion criteria, 46 patients (68.7%) were given anticoagulants and 21 patients (31.3%) were not given anticoagulants. The highest use of anticoagulants was in the age group of 55-65 years (n=28) and 30-54 years (n=21). Heparin (11.9%) and Rivaroxaban (9%) were the single anticoagulants most frequently used for hospitalized COVID-19 patients at Panembahan Hospital, Bantul, Yogyakarta. While the most used combinations were Heparin with Rivaroxaban (20.9%), and Enoxaparin with Rivaroxaban (9%).


Keywords


Anticoagulants COVID-19 Hypertension Panembahan Hospital Bantul Yogyakarta

Full Text:

PDF

References


Achmad, A. F., Raharjani, Y. I., Setyaningrum, Z., Andi, B., Selvyana, D. R., Pramesthi, S., & Bowo, W. (2022). Anticoagulant Therapy in Moderate to Severe COVID-19 Patients. 22(1), 69–74. https://doi.org/10.18196/mmjkk.v21i2.11634.

ATTACC, ACTIV-4a, and REMAP-CAP Investigators. (2021). Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. New England Journal of Medicine, 385(9), 790-802.

Beale, A. L., Meyer, P., Marwick, T. H., Lam, C. S., & Kaye, D. M. (2018). Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation, 138(2), 198-205.

Bikdeli, B., & Garcia, D. A. (2022). In high-risk inpatients with COVID-19, therapeutic-vs. standard-dose heparin reduced thromboembolism or death at 30 d. Annals of Internal Medicine, 175(2), JC17

Ciarambino, T., Ciaburri, F., Paoli, V. D., D’avino, M., & Campania, D. F. (2021). Gender differences in COVID-19 patients with arterial hypertension. Journal of Hypertension, 39, e204.

Cifkova, R., Pitha, J., Krajcoviechova, A., & Kralikova, E. (2019). Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. International journal of cardiology, 286, 214-219.

Doerre, A., & Doblhammer, G. (2022). The influence of gender on COVID-19 infections and mortality in Germany: Insights from age-and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. Plos one, 17(5), e0268119.

Farkouh, M. E., Stone, G. W., Lala, A., Bagiella, E., Moreno, P. R., Nadkarni, G. N., ... & Fuster, V. (2022). Anticoagulation in patients with COVID-19: JACC Review Topic of the Week. Journal of the American College of Cardiology, 79(9), 917-928.

Gillis, E. E., & Sullivan, J. C. (2016). Sex differences in hypertension: recent advances. Hypertension, 68(6), 1322-1327.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., & Gu, X. (2020). Articles Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China. 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Juni, P. J., Ayu, G., Giti, P., Devi, L., Aryabiantara, I. W., & Hartawan, I. U. (2018). Profil Penggunaan Antikoagulan Pada Pasien Kardiovaskular Yang Dirawat Di Ruang ICCU RSUP Sanglah Periode Januari 2016 - JUNI 2016. 7(10).

Karyono, D. R., & Wicaksana, A. L. (2020). Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health, 3(2), 77. https://doi.org/10.22146/jcoemph.57325

Komiyama, M., & Hasegawa, K. (2020). COVID-19 Anticoagulant Therapy for Patients with Coronavirus Disease 2019 : Urgent Need for Enhanced Awareness COVID-19. 2019–2021.

Klok, F. A., Kruip, M. J. H. A., Van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., ... & Endeman, H. (2020). Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis research, 191, 148-150.

Lalouel, J. M. (2003). Large-scale search for genes predisposing to essential hypertension. American journal of hypertension, 16(2), 163.

Levy, D., DeStefano, A. L., Larson, M. G., O’Donnell, C. J., Lifton, R. P., Gavras, H., ... & Myers, R. H. (2000). Evidence for a gene influencing blood pressure on chromosome 17: genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension, 36(4), 477-483.

Lin, L., Lu, L., Cao, W., & Li, T. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9 (1): 727-32. doi. org/10.1080/22221751.2020, 1746199.

Lopes, R. D., Furtado, R. H., Macedo, A. V. S., Bronhara, B., Damiani, L. P., Barbosa, L. M., ... & ACTION Coalition COVID-19 Brazil IV Investigators. (2021). Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. The Lancet, 397(10291), 2253-2263.

Maas, A. H. (2019). Hypertension in women: no “silent” lady-killer. EJ Cardiol Pract, 17, 11-21.

Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014). Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical pharmacokinetics, 53(1), 1-16.

Male, C., Lensing, A. W., Palumbo, J. S., Kumar, R., Nurmeev, I., Hege, K., ... & Berkow, R. (2020). Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology, 7(1), e18-e27.

Paranjpe, I., Fuster, V., Lala, A., Russak, A. J., Glicksberg, B. S., Levin, M. A., ... & Nadkarni, G. N. (2020). Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. Journal of the American College of Cardiology, 76(1), 122-124.

Parisi, R., Costanzo, S., Di Castelnuovo, A., De Gaetano, G., Donati, M. B., & Iacoviello, L. (2021, June). Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. In Seminars in thrombosis and hemostasis (Vol. 47, No. 04, pp. 372-391). Thieme Medical Publishers, Inc..

Parveen, R., Sehar, N., Bajpai, R., & Bharal, N. (2020). Association of diabetes and hypertension with disease severity in covid-19 patients : A systematic literature review and exploratory meta-analysis. January.

Ramacciotti, E., Agati, L. B., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., de Oliveira, C. C. C., ... & Santos, M. V. B. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 399(10319), 50-59.

Rana, B. K., Insel, P. A., Payne, S. H., Abel, K., Beutler, E., Ziegler, M. G., ... & O’Connor, D. T. (2007). Population-based sample reveals gene–gender interactions in blood pressure in White Americans. Hypertension, 49(1), 96-106.

Santoro, F., Núñez-Gil, I. J., Viana-Llamas, M. C., Maroun Eid, C., Romero, R., Fernandez Rozas, I., ... & Brunetti, N. D. (2021). Anticoagulation therapy in patients with coronavirus disease 2019: results from a multicenter international prospective registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19]). Critical Care Medicine, 49(6), e624-e633.

Shi, Y., Yu, X., Zhao, H., Wang, H., Zhao, R., & Sheng, J. (2020). Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Critical care, 24(1), 1-4.

Sholzberg, M., Tang, G. H., Rahhal, H., AlHamzah, M., Kreuziger, L. B., Áinle, F. N., ... & Jüni, P. (2021). Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. bmj, 375.

Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., ... & HEP-COVID Investigators. (2021). Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA internal medicine, 181(12), 1612-1620.

Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis, 18(5), 1094-1099.

Tarigan, A. R., Lubis, Z., & Syarifah, S. (2018). The Effect of Knowledge, Attitudes and Family Support on Hypertension Diet in Hulu Village, Pancur Batu District in 2016. Jurnal Kesehatan, 11(1), 9–17. https://doi.org/10.24252/kesehatan.v11i1.5107

Tunjungputri, R. N., Tetrasiwi, E. N., & Mulansari, N. A. (2022). Parenteral and Oral Anticoagulant Treatment for Hospitalized and Post-Discharge COVID-19 Patients : A Systematic Review and Meta-Analysis. 54(2).

Vahidy, F. S., Pan, A. P., Ahnstedt, H., Munshi, Y., Choi, H. A., Tiruneh, Y., ... & McCullough, L. D. (2021). Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PloS one, 16(1), e0245556.

Wenger, N. K., Arnold, A., Bairey Merz, C. N., Cooper-DeHoff, R. M., Ferdinand, K. C., Fleg, J. L., ... & Pepine, C. J. (2018). Hypertension across a woman’s life cycle. Journal of the American College of Cardiology, 71(16), 1797-1813




DOI: https://doi.org/10.31764/lf.v4i1.11554

Refbacks

  • There are currently no refbacks.


EDITORIAL OFFICE: